Home
Responsibility
Corporate responsibility at GSK
Corporate responsibility data summary

Corporate Responsibility Report 2008

Corporate responsibility data summary

Metric	2004	2005	2006	2007	2008
Access to medicines
Number of countries supplied with GSK preferentially priced ARVs¹	57	56	51	31	37
Number of Combivir and Epivir tablets shipped (millions)	66.4	126.3	86.3	85.0	70.0
Number of generic ARVs supplied under licence from GSK (millions)	-	-	120	183	279
GSK Combivir not-for-profit price ($ per day)²	0.65	0.65	0.65	0.54	0.54
Voluntary licences granted to generic manufacturers for GSK ARVs (cumulative total)³	6	7	9	9	9
Value of products donated through GSK Patient Assistance Program in the US (£ millions, 2008-2007 at cost, 2006-2004 at wholesale price (WAC))⁴	203	255	200	45	56

Research and Development
Expenditure on R&D (£ billions)	2.9	3.1	3.5	3.3	3.7
GSK animal research facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (cumulative total)⁵	10	10	10	10	10
Number of trials published on the GSK Clinical Study Register (cumulative total)	143	2,125	2,760	3,089	3,273

Ethical conduct
Number of employees completing certification to the GSK Code of Conduct	9600	>12,000	>12,000	>14,000	>14,000
Number of contacts through our ethics compliance channels⁶	2580	3644	5363	5265	3812

Employment
Women in management grades (%)	35	35	36	37	38
Ethnic diversity - people of colour (US, %)	19.5	19.6	19.8	20.1	20.5
Ethnic diversity - ethnic minorities (UK, %)	14.8	14.9	18.3	19.1	19.2
Lost time injury and illness rate (cases per 100,000 hours worked)	0.32	0.32	0.34	0.35	0.33

Environment
Number of contract manufacturers audited	35	41	36	55	53
Energy consumption (million gigajoules)	19	19	19	19	19
Water consumption (million cubic metres)	21	22	22	21	20
Ozone depletion potential from metered dose inhalers (tonnes CFC-11 equivalent)⁷	464	273	182	136	88
Ozone depletion potential from production (tonnes CFC-11 equivalent)	59	51	33	15	5
Ozone depletion potential from refrigeration and other ancillary uses (tonnes CFC-11 equivalent)	3	3	1	1	<1
Volatile organic compound emissions (thousand tonnes)	5	5	4	4	4
Global warming potential from energy sources (thousand tonnes CO₂ equivalent)⁸	1,667	1,717	1,704	1,702	1,722
Hazardous waste disposed (thousand tonnes)	71	67	70	72	54

Community investment
Total community investment expenditure (£ millions, 2008-2007 at cost, 2006-2004 at wholesale price (WAC))⁴	328	380	302	109	124
Value of humanitarian product donations, including albendazole (£ millions, 2008-2007 at cost, 2006-2004 at wholesale price (WAC))⁴	57	41	38	7	12
Number of albendazole tablets donated for prevention of lymphatic filariasis (millions)	67	136	155	150	266

1. Includes ARVs sold at not-for-profit and discounted prices. We are unable to collect data for the number of patients treated.

2. Includes freight and delivery costs. The M�decins Sans Fronti�res pricing report lists the average cost of generic equivalents.

3. Only eight are currently in force.

4. 2008 and restated 2007 figures reflect value at cost (average cost of goods) rather than wholesale acquisition price (WAC). This is the first year we have valued our donations this way and believe it is a more accurate reflection of the true cost to GSK and is therefore more transparent. 2004 to 2006 figures remain at WAC.

5. This covers over 90 per cent of the animals housed in GSK-owned laboratories.

6. Includes contacts with line managers, compliance officers, our confidential Integrity Helplines or offsite post office box (in the US).

7. 2004 data do not include inhalers made in Asia.

8. Climate change impact is calculated as CO₂ equivalent using the Greenhouse Gas Protocol developed by the World Resources Institute and the World Business Council for Sustainable Development. Each year we review the CO₂ factors and update the data for all years as appropriate. The greatest changes are generally in the updated factors for electricity.